ATE253903T1 - Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor - Google Patents

Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Info

Publication number
ATE253903T1
ATE253903T1 AT97952407T AT97952407T ATE253903T1 AT E253903 T1 ATE253903 T1 AT E253903T1 AT 97952407 T AT97952407 T AT 97952407T AT 97952407 T AT97952407 T AT 97952407T AT E253903 T1 ATE253903 T1 AT E253903T1
Authority
AT
Austria
Prior art keywords
ppar
agents
growth
preventing
methods
Prior art date
Application number
AT97952407T
Other languages
English (en)
Inventor
Bruce M Spiegelman
Soner Altiok
Elisabetta Mueller
Pasha Serraf
Peter Tontonoz
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/923,346 external-priority patent/US6552055B2/en
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE253903T1 publication Critical patent/ATE253903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97952407T 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor ATE253903T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76655396A 1996-12-11 1996-12-11
US08/923,346 US6552055B2 (en) 1996-12-11 1997-09-04 Methods and pharmaceutical compositions for inhibiting tumor cell growth
PCT/US1997/022879 WO1998025598A2 (en) 1996-12-11 1997-12-11 Methods and pharmaceutical compositions for inhibiting tumour cell growth

Publications (1)

Publication Number Publication Date
ATE253903T1 true ATE253903T1 (de) 2003-11-15

Family

ID=27117766

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03078539T ATE462433T1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
AT97952407T ATE253903T1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03078539T ATE462433T1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums

Country Status (8)

Country Link
US (1) US7635708B2 (de)
EP (2) EP1410799B1 (de)
JP (2) JP4549443B2 (de)
AT (2) ATE462433T1 (de)
AU (1) AU5601898A (de)
CA (1) CA2274756C (de)
DE (2) DE69739828D1 (de)
WO (1) WO1998025598A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029120A1 (en) * 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
FR2773075B1 (fr) * 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
AU1707599A (en) * 1998-03-20 1999-10-18 Warner-Lambert Company Retinoid-glitazone combinations
EP1143953A3 (de) * 1998-11-20 2002-02-06 Genentech, Inc. Verfahren zur hemmung der angiogenese
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
WO2002013864A1 (fr) * 2000-08-16 2002-02-21 Sankyo Company, Limited Preparation medicinale de prevention et traitement du cancer
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
WO2002080913A1 (en) * 2001-04-06 2002-10-17 F. Hoffmann-La Roche Ag Thiazolidinediones alone or in combination with other therapeutic agents for inhibiting or reducing tumour growth
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US20040197834A1 (en) * 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
AU2003220855A1 (en) * 2002-04-01 2003-10-13 Sankyo Company, Limited Medicinal antitumor composition
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
AU2003246187A1 (en) * 2002-06-25 2004-01-06 Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
KR101218213B1 (ko) * 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
CA2600712A1 (en) * 2005-03-14 2006-09-21 Immunomedics, Inc. Methods of treating cancer using ppar-gamma antagonists
US20080194646A1 (en) 2005-03-21 2008-08-14 Sanders Martin E Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders
DK1937244T3 (en) 2005-09-30 2018-10-29 Io Therapeutics Llc : CANCER TREATMENT WITH SPECIFIC RXR AGONISTS
CA2630816C (en) 2005-11-28 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
MX2009012600A (es) 2007-05-21 2010-03-15 Senju Pharma Co Farmaceutico que contiene el agonista ppar alfa.
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
CN103619168B (zh) 2011-06-29 2015-09-23 宾州研究基金会 用于治疗白血病的组合物、方法和药盒
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
JP5987175B2 (ja) * 2012-07-02 2016-09-07 学校法人福岡大学 乳癌，胃癌及び卵巣癌等に対する制癌剤
JP6453224B2 (ja) 2012-11-05 2019-01-16 コミッサリア ア レネルジ アトミック エ オー エネルジス アルテルナティヴスＣｏｍｍｉｓｓａｒｉａｔ Ａ Ｌ‘Ｅｎｅｒｇｉｅ Ａｔｏｍｉｑｕｅ Ｅｔ Ａｕｘ Ｅｎｅｒｇｉｅｓ Ａｌｔｅｒｎａｔｉｖｅｓ インビボで血液がんの幹細胞を排除するため、および血液がんの再発を防ぐための、チロシンキナーゼ阻害剤のような抗がん剤と、好ましくはチアゾリジンジオンであるｓｔａｔ５アンタゴニストとの組み合わせ
AU2015315324A1 (en) * 2014-09-08 2017-03-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer comprising administering a PPAR-gamma agonist
CN116077626A (zh) 2015-10-31 2023-05-09 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
WO2017075612A1 (en) * 2015-10-31 2017-05-04 Io Therapeutics, Inc. Treatment of cancer with combinations of rxr agonists and thyroid hormones
WO2017151836A1 (en) * 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10946001B2 (en) 2016-03-10 2021-03-16 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
AU2016396659B2 (en) 2016-03-10 2019-02-14 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
AU2018335393A1 (en) 2017-09-20 2020-04-02 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
JPWO2022054755A1 (de) * 2020-09-08 2022-03-17
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ES2149814T3 (es) * 1992-04-22 2000-11-16 Ligand Pharm Inc Compuestos que tienen selectividad para los receptores de retinoides x.
US5552271A (en) 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5521202A (en) 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
JPH09505731A (ja) 1993-10-22 1997-06-10 リガンド・ファーマシューティカルズ・インコーポレーテッド ヒトペルオキシソーム増殖因子活性化レセプター
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
US5514821A (en) 1994-05-27 1996-05-07 Ligand Pharmaceuticals Incorporated Ring-labeled retinoids and intermediates, and methods for their synthesis and use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
WO1996001430A2 (en) 1994-07-01 1996-01-18 Ligand Pharmaceuticals, Incorporated Screening for nuc inhibitors
CA2194169A1 (en) 1994-07-01 1996-01-18 Ronald M. Evans Mammalian peroxisome proliferator-activated receptors and uses thereof
CZ288526B6 (cs) 1994-08-10 2001-07-11 F. Hoffmann-La Roche Ag Deriváty tetrahydronaftalenu nebo indanu, farmaceutické přípravky na jejich bázi a meziprodukty pro přípravu těchto derivátů
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH11511004A (ja) * 1995-05-04 1999-09-28 シティ・オブ・ホープ ヒト白血球１２−リポキシゲナーゼおよび疾病状態の病因でのその役割
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
EP1426048A3 (de) * 1995-09-18 2004-06-16 Ligand Pharmaceuticals, Inc. Behandlung der Hypertriglyceridämie mit RXR Agonisten in Kombination mit einem PPARgamma Agonist
WO1997017091A1 (en) * 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
JP4549443B2 (ja) 2010-09-22
WO1998025598A2 (en) 1998-06-18
EP0948324B1 (de) 2003-11-12
WO1998025598A3 (en) 1998-07-30
US7635708B2 (en) 2009-12-22
US20030144330A1 (en) 2003-07-31
JP2001510462A (ja) 2001-07-31
EP0948324A2 (de) 1999-10-13
EP1410799B1 (de) 2010-03-31
EP1410799A1 (de) 2004-04-21
ATE462433T1 (de) 2010-04-15
JP4550133B2 (ja) 2010-09-22
CA2274756A1 (en) 1998-06-18
DE69739828D1 (de) 2010-05-12
JP2009063566A (ja) 2009-03-26
AU5601898A (en) 1998-07-03
DE69726182D1 (de) 2003-12-18
CA2274756C (en) 2007-03-13
DE69726182T2 (de) 2004-08-12

Similar Documents

Publication Publication Date Title
ATE253903T1 (de) Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
ES2153337T1 (es) Inhibidores de raf-quinasa.
HK1029989A1 (en) Inhibition of raf kinase using aryl and heteroarylsubstituted heterocyclic ureas
TR199802385T2 (xx) TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
BR9814374B1 (pt) "urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas"
DE60045474D1 (de) Neues verfahren zum erschaffen von proteinkinase-inhibitoren
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
WO1993021942A3 (en) Use of mmp inhibitors
DE60038951D1 (de) Verfahren zur inhibierung von gehirntumorwachstum durch verwendung von antagonisten von integrinen
ATE374642T1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
ATE72939T1 (de) Verwendung von enzymatisch aufloesbaren zusammensetzungen zum ueberziehen von futtermittelzusatzmitteln fuer wiederkaeuer.
ATE418999T1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
AR024138A1 (es) Inhibidores de la proliferacion celular
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE3672086D1 (de) Synergistische, antimikrobische beimischungen, enthaltend 2-bromo-2-bromomethylglutaronitril, verfahren zur hemmung mikrobischen wachstums und gegen mikrobisches wachstum geschuetzte substrate.
ATE232191T1 (de) Verfahren und zusammensetzung zur inhibierung der polymerisierung von ethylenisch ungesättigten kohlenwasserstoffen
NO20010389D0 (no) Modulering av multippel linje-kinaseproteiner
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
DE60019946D1 (de) Antisense-modulation von x-verbundenen inhibitoren der apoptosis-expression
DE3577456D1 (de) Fluessige zusammensetzung zur behandlung von metalloberflaechen.
DE69936234D1 (de) Verfahren und Zusammenstzung zur Hemmung des Wachtums von neoplastischen Zellen
DE3585919D1 (de) Verfahren zur behandlung von zellen.
ATE225660T1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0948324

Country of ref document: EP